The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future

Table 4

Trials of treatments for early stage unfavourable Hodgkin’s lymphoma. Numbers in bold are statistically significant with 𝑃 values where significant. ^∗Treatment discontinuation due to haematological intolerance. Abbreviations: OS: overall survival; EF RT: extended-field radiotherapy; IF-RT: involved-field radiotherapy; STLI: subtotal lymphoid irradiation; Gy: gray; ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine; EBVP: epirubicin, bleomycin, vinblastine, and prednisolone; MOPP/ABV: mechlorethamine, vincristine, procarbazine, prednisolone, doxorubicin, bleomycin, and vinblastine; COPP/ABVD: cyclophosphamide, vincristine, procarbazine, and prednisolone/ABVD; BEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisolone.

Treatment regimen; (author/trial)	No. of Pts	Outcome; (%, measure, time)	OS (%)	Haem toxicity; (% grade III-IV)	Second malignancy (haem/solid, %)
3 MOPP + Mantle RT + 3 MOPP	165	77 (FFP 6 y)	85	14.5	—
3 ABVD + Mantle + 3 ABVD	151	88	91	7.3*	—
(Carde EORTC H6U 1993)		𝑃=.01
6EBVP + IF RT (36 Gy)	194	68 (EFS 10 y)	79	—	4/5
6 MOPP/ABV + IF RT	195	88	87	—	2/2
(Noordijk EORTC H7U 2006)		𝑃<.001	𝑃=.0175
2ABVD + STLI	139	95 (FFP 5 y)	92	—	—
4–6ABVD	137	88	95	—	—
(Meyer NCI-C/ECOG HD6 2005)		𝑃=.004
6 MOPP/ABV + IF RT (36 Gy)	336	82 (EFS 10 y)	88	—	2/2
4 MOPP/ABV + IF RT (36 Gy)	333	80	85	—	3/3
4 MOPP/ABV + STLI	327	80	84	—	2/2
(Ferme EORTC-GELA H8U 2000)
4 COPP/ABVD + EF RT (30 Gy) + Bulky 10 Gy	532	86 (FFTF 5 y)	91	5.8	2.2/2.3
4 COPP/ABVD + IF RT (30 Gy) + Bulky 10 Gy	532	84	92	2.5	1.2/1.7
(Engert GHSG HD8 2003)				𝑃<.001